Urinary excretion of material with beta-endorphin immunoreactivity
Denko, C.W.; Gabriel, P.; Petricevic, M.
Clinical Chemistry 27(1): 207-208
1981
ISSN/ISBN: 0009-9147 PMID: 6256097 Document Number: 171201
Document emailed within 1 workday
Related Documents
Kuhn, E.; Lodin, Z.; Lovacký, S.; Tauber, O.; Zizkovský, V.; Dvorák, P.; Srajer, S.; Skála, I. 1986: Plasma beta-endorphin immunoreactivity (PL-beta-ED-ir) in patients with ulcer disease and its management by acute and chronic administration of gastrozepin Hepato-Gastroenterology 33(1): 23-26Golanov, E.V.; Fufacheva, A.A.; Parin, S.B. 1985: Beta-endorphin-like immunoreactivity of the blood plasma of hamadryas baboons and its changes Biulleten' Eksperimental'noi Biologii i Meditsiny 100(12): 677-679
Alföldi, A.; Simkó, K.; Fekete, M.I.; Farsang, C. 1991: Adrenergic and dopaminergic regulation of circulating beta-endorphin-like immunoreactivity in hypertension Acta Physiologica Hungarica 78(1): 99-106
Pasi, A.; Moccetti, T.; Legler, M.; Mueller, J.; Foletta, D.; Gramsch, C.; Hartmann, H. 1983: Elevation of blood levels of beta-endorphin-like immunoreactivity in patients with shock Research Communications in Chemical Pathology and Pharmacology 42(3): 509-512
Mitsuma, T.; Hirooka, Y.; Nomura, A.; Okamoto, H.; Nogimori, T. 1988: Effects of eel calcitonin on plasma beta-endorphin-like immunoreactivity levels in rats Endocrinologia Experimentalis 22(2): 107-112
Rees, M.; Bowen, J.C.; Payne, J.G.; MacPhee, A.A. 1983: Plasma beta-endorphin immunoreactivity in dogs during anesthesia, surgery, Escherichia coli sepsis, and naloxone therapy Surgery 93(3): 386-390
Clerico, A.; Cambi, A.; Del Chicca, M.G.; Cecchini, L.; Giaconi, S. 1988: Urinary excretion of digoxin-like immunoreactivity after physical exercise Clinical Chemistry 34(1): 215
Bhargava, H.N.; Matwyshyn, G.A.; Rattan, A.K.; Koo, K.L.; Tejwani, G.A. 1994: beta-Endorphin-like immunoreactivity in discrete brain regions, spinal cord, pituitary gland and peripheral tissues of U-50,488H-tolerant and -abstinent rats Journal of Pharmacology and Experimental Therapeutics 268(2): 856-861
Nagao, K.; Higashimoto, Y.; Shinomura, Y.; Himeno, S.; Miyazaki, Y.; Yasunaga, Y.; Tarui, S. 1990: Temporal profiles of urinary excretion of NH2-terminal big gastrin immunoreactivity in humans American Journal of Gastroenterology 85(11): 1489-1492
Worgall, S.; Manz, F.; Kleschin, K.; Feth, F.; Rascher, W. 1994: Elevated urinary excretion of endothelin-like immunoreactivity in children with renal disease is related to urine flow rate Clinical Nephrology 41(6): 331-337
Burbach, J.P.; Loeber, J.G.; Verhoef, J.; Wiegant, V.M.; de Kloet, E.R.; de Wied, D. 1980: Selective conversion of beta-endorphin into peptides related to gamma- and alpha-endorphin Nature 283(5742): 96-97
Katavetin, P.; Eiam-Ong, S.; Suwanwalaikorn, S. 2006: Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy Journal of the Medical Association of Thailand 89(2): 170-177
Eriksson, E.; Westberg, P.; Thuresson, K.; Modigh, K.; Ekman, R.; Widerlöv, E. 1989: Increased cerebrospinal fluid levels of endorphin immunoreactivity in panic disorder Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2(3): 225-228
Krämer, B.K.; Ress, K.M.; Erley, C.M.; Risler, T. 1991: Effects of beta-blockade on urinary albumin excretion in normal subjects International Journal of Clinical Pharmacology Research 11(6): 271-274
Cecchi, R.; Giomi, A.; Ciuti, M.; Seghieri, G. 1996: Increased urinary excretion of N-acetyl-beta-D-glucosaminidase in patients affected with psoriasis Acta Dermato-Venereologica 76(6): 492
Zandvliet, E.E.; Giesberts, M.A.; van Gelderen, H.H. 1983: The excretion of N-acetyl-beta-D-glucosaminidase in the urine of children with urinary tract diseases Tijdschrift Voor Kindergeneeskunde 51(4): 135-138
Semczuk-Sikora, A.; Sikora, P.ła.; Biaduń, U.; Semczuk, M. 2003: Urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion in women with pregnancy complicated with hypertension Ginekologia Polska 74(10): 1269-1275
Minami, M.; Togashi, H.; Sano, M.; Yoshioka, M.; Saito, I.; Morii, K.; Tochihara, M.; Hirogami, M.; Nomura, A.; Saito, H. 1985: Effects of new antihypertensive agent, 2-[4-(n-butyryl)-homopiperazine-1-ul]-4-amino-6, 7-dimethoxy-quinazoline (E-643), on blood pressure, urinary sodium excretion and urinary norepinephrine excretion rate in stroke-prone, spontaneously hypertensive rats Hokkaido Journal of Medical Science 60(4): 536-543
Arao, M.; Matsumiya, K.; Hasegawa, K.; Horiuchi, N.; Sasaki, A. 1989: Changes in urinary excretion of N-acetyl-beta-D-glucosaminidase (NAG) during follow-up period and related factors in diabetic patients Rinsho Byori. Japanese Journal of Clinical Pathology 37(1): 37-42
Neftel, K.A.; Käser, H.E.; Vorkauf, H. 1984: Different effects of selective and nonselective beta adrenoceptor blockade on urinary catecholamine and creatinine excretion in stress International Journal of Clinical Pharmacology Therapy and Toxicology 22(2): 118-119